Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program
Jingwei Li, Sunil V. Badve, Zien Zhou, et al.
The Lancet Rheumatology (2019) Vol. 1, Iss. 4, pp. e220-e228
Open Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
Paul E. Stevens, Sofia B. Ahmed, Juan Jesús Carrero, et al.
Kidney International (2024) Vol. 105, Iss. 4, pp. S117-S314
Open Access | Times Cited: 1997
Gout
Nicola Dalbeth, Anna L. Gosling, Angelo Gaffo, et al.
The Lancet (2021) Vol. 397, Iss. 10287, pp. 1843-1855
Closed Access | Times Cited: 811
Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association
Janani Rangaswami, Vivek Bhalla, Ian H. de Boer, et al.
Circulation (2020) Vol. 142, Iss. 17
Open Access | Times Cited: 145
Kidney-Protective Effects of SGLT2 Inhibitors
Biff F. Palmer, Deborah J. Clegg
Clinical Journal of the American Society of Nephrology (2022) Vol. 18, Iss. 2, pp. 279-289
Open Access | Times Cited: 58
Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF
Kirsty McDowell, Paul Welsh, Kieran F. Docherty, et al.
European Journal of Heart Failure (2022) Vol. 24, Iss. 6, pp. 1066-1076
Open Access | Times Cited: 47
Gout Flares and Mortality After Sodium-Glucose Cotransporter-2 Inhibitor Treatment for Gout and Type 2 Diabetes
Jie Wei, Hyon K. Choi, Nicola Dalbeth, et al.
JAMA Network Open (2023) Vol. 6, Iss. 8, pp. e2330885-e2330885
Open Access | Times Cited: 25
Serum uric acid lowering and effects of sodium‐glucose cotransporter‐2 inhibitors on gout: A meta‐analysis and meta‐regression of randomized controlled trials
Mainak Banerjee, Rimesh Pal, Indira Maisnam, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 9, pp. 2697-2703
Closed Access | Times Cited: 23
The clinical benefits of sodium–glucose cotransporter type 2 inhibitors in people with gout
Chio Yokose, Natalie McCormick, Abhishek Abhishek, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 4, pp. 216-231
Closed Access | Times Cited: 14
SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review
Samuel Seidu, Vicki Alabraba, Sarah Davies, et al.
Diabetes Therapy (2024) Vol. 15, Iss. 5, pp. 1099-1124
Open Access | Times Cited: 10
Reducing hyperuricemic events with SGLT2 inhibitors: An updated systematic review with meta-regression
Hamlet Ghukasyan, Denilsa Navalha, Ignacio Pérez Romero, et al.
Endocrinología Diabetes y Nutrición (English ed ) (2025) Vol. 72, Iss. 1, pp. 26-36
Closed Access | Times Cited: 1
Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA‐REG OUTCOME trial
João Pedro Ferreira, Silvio E. Inzucchi, Michaela Mattheus, et al.
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. 1, pp. 135-141
Open Access | Times Cited: 50
Lower risk of gout in sodium glucose cotransporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP4) inhibitors in type-2 diabetes
Jiandong Zhou, Xuejin Liu, Oscar Hou In Chou, et al.
Lara D. Veeken (2022) Vol. 62, Iss. 4, pp. 1501-1510
Closed Access | Times Cited: 31
Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis
Phil McEwan, Rebecca Boyce, Juan José García Sánchez, et al.
Nephrology Dialysis Transplantation (2022) Vol. 38, Iss. 5, pp. 1260-1270
Open Access | Times Cited: 26
Can SGLT2 inhibitors prevent incident gout? A systematic review and meta-analysis
Mainak Banerjee, Rimesh Pal, Satinath Mukhopadhyay
Acta Diabetologica (2022) Vol. 59, Iss. 6, pp. 783-791
Closed Access | Times Cited: 24
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
Kaitlin J. Mayne, Rebecca J. Sardell, Natalie Staplin, et al.
Nephrology Dialysis Transplantation (2024)
Closed Access | Times Cited: 6
Management of Type 2 Diabetic Kidney Disease in 2022: A Narrative Review for Specialists and Primary Care
David Z.I. Cherney, Alan Bell, Louis Girard, et al.
Canadian Journal of Kidney Health and Disease (2023) Vol. 10
Open Access | Times Cited: 10
Sodium-glucose cotransporter-2 inhibitors use and the risk of gout: a systematic review and meta-analysis
Shih‐Wei Lai, Bing‐Fang Hwang, Yu‐Hung Kuo, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 10
Dual benefits of sodium-glucose cotransporter 2 inhibitors in metabolic diseases: Diabetes control and gout management
Xiao-Peng Fu
World Journal of Clinical Cases (2025) Vol. 13, Iss. 14
Closed Access
The Short and Sweet on Sodium–Glucose Cotransporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure
José López, Tracy Makuvire, Jonathan D. Davis, et al.
US Cardiology Review (2025) Vol. 19
Open Access
Glucose, Fructose, and Urate Transporters in the Choroid Plexus Epithelium
Yoichi Chiba, Ryuta Murakami, Koichí Matsumoto, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 19, pp. 7230-7230
Open Access | Times Cited: 27
Sodium glucose cotransporter 2 inhibitors and gout risk: a sequence symmetry analysis
D. Wood, Nancee V. Waterbury, Brian C. Lund
Clinical Rheumatology (2023) Vol. 42, Iss. 9, pp. 2469-2475
Closed Access | Times Cited: 9
Sodium–Glucose Cotransporter 2 Inhibitors to Decrease the Uric Acid Concentration—A Novel Mechanism of Action
Anna Kochanowska, Przemysław Rusztyn, Karolina Szczerkowska, et al.
Journal of Cardiovascular Development and Disease (2023) Vol. 10, Iss. 7, pp. 268-268
Open Access | Times Cited: 9
SGLT2 Inhibitors, but Not GLP-1 Receptor Agonists, Reduce Incidence of Gout in People Living With Type 2 Diabetes Across the Therapeutic Spectrum
Frank Preston, Matthew Anson, David R. Riley, et al.
Clinical Therapeutics (2024)
Open Access | Times Cited: 3
Chapter 2: Clinical and Mechanistic Potential of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors in Heart Failure with Preserved Ejection Fraction
John W. Ostrominski, Muthiah Vaduganathan
The American Journal of Medicine (2023) Vol. 137, Iss. 2, pp. S9-S24
Closed Access | Times Cited: 7
Effects of ertugliflozin on uric acid and gout‐related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV
Vikas S. Sridhar, Francesco Cosentino, Samuel Dagogo‐Jack, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 11, pp. 5336-5346
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top